Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

Nano-Engineered Products Are Not GRAS-Ready - Experts

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

You may also be interested in...



FDA Nanotech Guidance Takes Small Step Forward

FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.

FDA Nanotech Guidance Takes Small Step Forward

FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.

FDA Nanotech Guidance Takes Small Step Forward

FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
HBW Insight
Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development

‘Stop Fighting Us’ On Inspections, US FDA’s Califf Tells Industry; Foods Modernization Will Bring ‘Big Change’ To Drug Quality Systems

US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends

Biogen/Ionis’ Tofersen: US FDA Considering Both Accelerated And Regular Approval In ALS

See All
UsernamePublicRestriction

Register

PS102099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By